GW Pharmaceuticals have announced that data from a phase III US clinical trial of Epidiolex (a cannabidiol oral solution) in people living with tuberous sclerosis complex (TSC) is expected in the first half of 2019. Epidiolex is currently approved in the United States as a

  The TSA office will be closed for the 2018 Christmas period between Tuesday 25 December 2018 and Tuesday 1 January 2019. Although some members of the team will still be around during some of this time, responses from us may take longer than usual

The TSA is delighted to announce that NHS England has backed recommendations from the Clinical Priorities Advisory Group to fund everolimus for the treatment of refractory epilepsy in people with Tuberous Sclerosis Complex (TSC) in England. Everolimus will be funded from April 2019. NHS England’s